

## **CBD Life Sciences Inc. (CBDL) Announces CBG Emerges as a Promising Focus in Cancer Research Initiatives**

*With the global cannabinoid market projected to surpass \$50+ billion in the coming years and segments like minor cannabinoids expected to grow at double-digit CAGR, cannabigerol (CBG) is rapidly emerging as a high-growth frontier—drawing attention for its non-psychoactive profile and early-stage research highlighting potential roles in oncology pathways and treatment support.*

---

**SCOTTSDALE, AZ / March 24, 2026 /** — CBD Life Sciences Inc. (OTC: CBDL), an emerging leader in cannabinoid innovation and high-growth wellness markets, today announced a major expansion of its **CBG-focused product program**, strategically positioning the Company at the forefront of one of the most promising segments in the evolving cannabinoid landscape.

The expansion includes the launch of **CBG-infused vape cartridges, tinctures, and advanced pain relief creams**, as CBDL aligns with accelerating scientific interest and consumer demand surrounding cannabigerol (CBG).

---

### **CBG: A Next-Generation Cannabinoid Gaining Scientific Traction**

While the U.S. Food and Drug Administration (FDA) has not approved CBG as a treatment for cancer, **a growing body of preclinical research is driving increased attention from both the scientific community and investors.**

Studies published through respected research institutions, including the National Institutes of Health (NIH) and PubMed Central (PMC), suggest that CBG may influence cancer-related biological pathways through several mechanisms:

- **Inducing apoptosis (programmed cell death)** in cancer cells, including colorectal carcinoma, glioblastoma, and leukemia
- **Disrupting tumor growth cycles** through cell cycle arrest
- **Interacting with key receptors** such as TRPM8 and PPAR $\gamma$ , which are associated with tumor progression and suppression
- **Targeting therapy-resistant cancer stem cells**, particularly in aggressive cancers like glioblastoma

These early findings are fueling **increased global interest in CBG as a compound of significance in next-generation cannabinoid research.**

---

## Expanding Role in Supportive Care Markets

In addition to tumor-related research, CBG is being explored for its potential to support patients undergoing conventional treatments such as chemotherapy—an area representing a significant and growing market opportunity:

- **Appetite stimulation** without psychoactive effects
- **Neuropathic pain relief**, including chemotherapy-induced nerve damage
- **Nausea modulation**, with ongoing research into dosage optimization

This dual potential—spanning both **research-driven oncology interest and high-demand wellness applications**—positions CBG as a uniquely valuable cannabinoid within the industry.

---

## CBDL Expands Product Portfolio to Capture Demand

CBD Life Sciences is actively capitalizing on this momentum with a targeted rollout of premium CBG products designed for scalability, consumer adoption, and market differentiation:

- **CBG Vape Cartridges** – Fast-acting delivery for immediate absorption
- **CBG Tinctures** – Precise, versatile dosing for daily wellness routines
- **CBG Pain Relief Creams** – Advanced topical formulations targeting inflammation and localized discomfort

This expansion reflects CBDL’s commitment to **innovation, product diversification, and capturing emerging high-margin categories** within the cannabinoid sector.

---

## Leadership Perspective: Positioning for Long-Term Growth

“CBG represents one of the most exciting opportunities we’ve seen in the cannabinoid space,” said **Lisa Nelson, President and Chief Executive Officer of CBD Life Sciences Inc.** “As research continues to uncover its potential, we are moving aggressively to position CBDL at the center of this emerging market. Our focus is on building a strong product ecosystem around CBG while delivering long-term value to our shareholders.”

---

## Strategic Alignment with a High-Growth Industry

As the cannabinoid market continues its rapid expansion, **CBG is quickly emerging as a key differentiator for forward-thinking companies.** Its non-psychoactive nature, combined with increasing scientific attention and consumer awareness, is driving a new wave of demand across both retail and research-driven segments.

CBDL believes its early entry and focused investment in CBG product development positions the Company to:

- Capture **first-mover advantage** in an emerging cannabinoid category
- Expand **market share across multiple product verticals**
- Strengthen **brand authority in next-generation cannabinoid innovation**
- Drive **long-term revenue growth and shareholder value**

### **About CBD Life Sciences Inc. (CBDL)**

CBD Life Sciences Inc. (OTC: CBDL) is a high-growth innovator in the cannabinoid and functional wellness sector, focused on developing and commercializing premium CBD and next-generation cannabinoid products. With a rapidly expanding product portfolio and increasing presence across major retail and e-commerce platforms—including Walmart Marketplace—the Company is executing on a strategy designed to capture significant market share in a multi-billion-dollar industry.

Driven by innovation, strategic expansion, and a commitment to quality, CBDL is actively positioning itself at the forefront of emerging cannabinoid trends, including CBG and other high-potential compounds. As the Company continues to scale distribution and product offerings, it remains focused on accelerating revenue growth, strengthening brand recognition, and maximizing long-term shareholder value.

### **Follow our social media for the latest updates!**

X: [https://www.x.com/CBDL\\_StockOTC](https://www.x.com/CBDL_StockOTC)

Instagram: <https://www.instagram.com/cbd.vault>

IR Contact: [cbdvaultaz@gmail.com](mailto:cbdvaultaz@gmail.com)

### **Stay Connected & Be the First to Try Our New Functional Mushroom Products!**

**Mushroom Madness Instagram:** <https://www.instagram.com/mushroom.madnessaz>

**Mushroom Madness Website:** <https://www.mushroommadness.shop>

### **Forward-Looking Statements**

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

**Safe Harbor Statement**

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

**Contact Information**

Lisa Nelson

CEO

[cbdvaultaz@gmail.com](mailto:cbdvaultaz@gmail.com)

4802091720

**SOURCE:** CBD Life Sciences Inc.